Treatment of Influenza Pneumonia

Introduction to Treatment

The American College of Physicians recommends dual-pathway treatment for influenza pneumonia, consisting of immediate oseltamivir antiviral therapy plus antibiotics stratified by severity, with the critical distinction being whether pneumonia is non-severe or severe 1, 2, 3

The Infectious Diseases Society of America recommends starting oseltamivir 75 mg orally every 12 hours for 5 days immediately upon diagnosis of influenza pneumonia, regardless of timing from symptom onset 1, 2
Hospitalized patients with pneumonia benefit from oseltamivir even when started >48 hours after symptom onset, particularly if immunocompromised 1, 2, 3
Dose adjustment is required if creatinine clearance <30 mL/min: reduce to 75 mg once daily 1

The American Thoracic Society recommends first-line oral co-amoxiclav (amoxicillin-clavulanate) or doxycycline for non-severe influenza-related pneumonia (CURB-65 Score 0-2) 1, 2, 3
The Infectious Diseases Society of America recommends immediate IV combination therapy with co-amoxiclav or 2nd/3rd generation cephalosporin (cefuroxime or cefotaxime) plus macrolide (clarithromycin or erythromycin) for severe influenza-related pneumonia (CURB-65 Score ≥3 or bilateral infiltrates) 1, 2, 3
Antibiotics must be administered within 4 hours of admission 1, 2
Duration of antibiotics is 7 days for uncomplicated pneumonia and 10 days for severe, microbiologically undefined pneumonia 1, 2, 3

Elderly and immunocompromised patients may not mount adequate febrile response but still require antiviral treatment based on clinical presentation 1, 2, 4
Patients with renal impairment (CrCl <30 mL/min) require oseltamivir dose reduction to 75 mg once daily 1

Oxygen therapy should be used to maintain SpO2 >92% or PaO2 >8 kPa 5
Antipyretics such as acetaminophen or ibuprofen should be used for fever control, but never aspirin in children <16 years due to Reye's syndrome risk 3, 4
Adequate hydration should be maintained through oral or IV fluids if necessary 3, 4

The British Thoracic Society recommends oral co-amoxiclav 625 mg three times daily as the preferred first-line antibiotic regimen for non-severe pneumonia (CURB-65 Score 0-2) 6, 7, 8
The British Thoracic Society suggests that co-amoxiclav provides coverage for the key bacterial pathogens in influenza-related pneumonia, including S. pneumoniae, H. influenzae, M. catarrhalis, and S. aureus 6, 7, 9
For severe pneumonia (CURB-65 Score ≥3 or Bilateral Infiltrates), the British Thoracic Society recommends immediate IV combination therapy with co-amoxiclav 1.2 g three times daily and a macrolide 6, 7, 8

The Journal of Infection suggests that influenza-related pneumonia has a unique bacterial pathogen profile requiring S. aureus coverage, which is not routinely needed in typical community-acquired pneumonia 6, 7, 9
Co-amoxiclav provides beta-lactamase stability against H. influenzae and M. catarrhalis, both common in post-influenza bacterial superinfection 6, 7, 9

The British Thoracic Society recommends switching from IV to oral antibiotics when clinically improved, afebrile for 24 hours, and able to tolerate oral intake 6

The British Thoracic Society advises against using macrolide monotherapy for influenza-related pneumonia and recommends combination therapy with a beta-lactam for severe disease 6, 7, 8
The British Thoracic Society emphasizes the importance of starting empirical antibiotic therapy immediately, without delay, as delays beyond 4 hours increase mortality 6, 7

The British Thoracic Society suggests respiratory fluoroquinolones, such as levofloxacin 500 mg once daily or moxifloxacin 400 mg once daily, as alternative regimens for patients intolerant of penicillins or with local resistance patterns 6, 7, 8